Live tape
Top 8, mentions 7d14,338NVDA4,854 mentions▲ +0.04GOOGL2,061 mentions▲ +0.04SPY1,736 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,106 mentions▲ +0.05TSLA954 mentions▲ +0.04SNDK861 mentions▲ +0.05

Equity · Healthcare

TVTX

NASDAQ

Travere Therapeutics (TVTX)

57 USD +3.15% vs prior close
Travere Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
5.5B USD
Revenue, year to Dec 2025
490.7M USD
EPS, diluted, year to Dec 2025
−0.29 USD
52-week range
15.33 USD – 59 USD
Avg volume
360.2K

as of Jul 17, 2026

Have Travere Therapeutics (TVTX) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, Travere Therapeutics insiders reported 17 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 15 Apr 2026, show no open-market purchase.

Form 4, 90 days to 10 Nov 2026, newest reported trade 15 Oct 2026

0buys
17sells
$80.13Mnet sold
16other filings
Have Travere Therapeutics (TVTX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
15 Oct 2026Dube Eric MCHIEF EXECUTIVE OFFICERSell243,73513.1M USD
17 Sep 2026Dube Eric MCHIEF EXECUTIVE OFFICERSell108,4937.0M USD
17 Sep 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICERSell8,282539K USD
16 Sep 2026Dube Eric MCHIEF EXECUTIVE OFFICERSell195,84112.4M USD
16 Sep 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICERSell172,71711.0M USD
16 Sep 2026ROTE WILLIAM E.Chief Research OfficerSell112,8507.1M USD
15 Sep 2026Calvin SandraSVP, CHIEF ACCOUNTING OFFICERSell5,375335K USD
15 Sep 2026Cline Christopher R.CHIEF FINANCIAL OFFICERSell50,5083.1M USD
15 Sep 2026Dube Eric MCHIEF EXECUTIVE OFFICERSell95,6666.0M USD
15 Sep 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICERSell102,1906.4M USD
15 Sep 2026Inrig JulaEVP, Head of R&D & CMOSell44,6742.8M USD
15 Sep 2026REED ELIZABETH EChief Legal Officer and GCSell37,5002.3M USD
Sold17 open-market sales1,304,671$80.13M

Showing the 12 most recent of 17 open-market trades in this window. The figures above count all of them.

16 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Travere Therapeutics (TVTX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
15 Oct 2026Dube Eric MCHIEF EXECUTIVE OFFICEROption exercise243,7353.0M USD
17 Sep 2026Dube Eric MCHIEF EXECUTIVE OFFICEROption exercise108,4932.5M USD
17 Sep 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICEROption exercise8,282186K USD
16 Sep 2026Dube Eric MCHIEF EXECUTIVE OFFICEROption exercise195,8414.6M USD
16 Sep 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICEROption exercise172,7172.5M USD
16 Sep 2026ROTE WILLIAM E.Chief Research OfficerOption exercise112,8502.4M USD
15 Sep 2026Calvin SandraSVP, CHIEF ACCOUNTING OFFICEROption exercise5,375130K USD
15 Sep 2026Cline Christopher R.CHIEF FINANCIAL OFFICEROption exercise20,000349K USD
15 Sep 2026Dube Eric MCHIEF EXECUTIVE OFFICEROption exercise95,6662.2M USD
15 Sep 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICEROption exercise77,1901.4M USD
15 Sep 2026Inrig JulaEVP, Head of R&D & CMOOption exercise32,395289K USD
15 Sep 2026REED ELIZABETH EChief Legal Officer and GCOption exercise37,500580K USD

Showing the 12 most recent of 16 compensation filings in this window. The figures above count all of them.

Which funds hold Travere Therapeutics (TVTX)?

1 of the 45 institutional funds we track reported a Travere Therapeutics position for the quarter ended 30 Sep 2026 — a combined 839K USD; the latest of those filings landed 06 Nov 2026.

Form 13F

Which funds hold Travere Therapeutics (TVTX)?
FundPositionSharesValueShares q/q
Fisher Asset ManagementHeld (±25%)14,247839K USD−10.1%

What has been filed or recorded for Travere Therapeutics (TVTX)?

The filings we hold for Travere Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Travere Therapeutics (TVTX)?
And
13 Oct 2026Fails to deliverShares failed to deliver144 shares7K USD notional · <0.001% of shares out
05 Oct 2026Fails to deliverShares failed to deliver1 shares57 USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.55 USD
30 Sep 2026FinancialsTotal assets848.2M USDat period end
30 Sep 2026FinancialsTotal equity22.6M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.37 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.40 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −0.29 USD
31 Dec 2025FinancialsRevenue490.7M USDfiscal year
31 Dec 2025FinancialsNet income−25.5M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−0.29 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS 0.28 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.14 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.47 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −4.08 USD

What do people ask about Travere Therapeutics (TVTX)?

From live data
What is Travere Therapeutics’ market cap?5.5B

Travere Therapeutics is worth 5.5B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is Travere Therapeutics’ revenue?490.7M

Travere Therapeutics reported revenue of 490.7M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Travere Therapeutics insiders bought or sold shares recently?17 sales

In the 90 days to 10 Nov 2026, Travere Therapeutics insiders reported 17 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 15 Apr 2026, show no open-market purchase. A further 16 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Travere Therapeutics?1 of 45

1 of the 45 funds we track reported a Travere Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds

When did Travere Therapeutics last report earnings?−0.55

Travere Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.55 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings